Recombinant Human VSTM2A His-tag Protein, CF

Recombinant Human VSTM2A (Catalog # 10037-VT) inhibits IFN-gamma secretion by human peripheral blood mononuclear cells in the presence ofanti-CD3 antibody. The ED50 for this effect is 1-10 μg/mL.

2 μg/lane of Recombinant Human VSTM2A was resolved with SDS-PAGE underreducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Bluestaining, showing bands at 38-42 kDa.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human VSTM2A His-tag Protein, CF Summary

• Details of Functionality: Measured by its ability to inhibit anti-CD3 antibody induced IFN-gamma secretion by human peripheral blood mononuclear cells (PBMC). The ED₅₀ for this effect is 1-10 μg/mL.
• Source: Human embryonic kidney cell, HEK293-derived human VSTM2A protein
  Ser25-Phe244, with a C-terminal 6-His tag
• Accession #: Q8TAG5-2
• N-terminal Sequence: Ser25
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 25 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 38-42 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, ≤ -20 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, ≤ -20 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 200 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human VSTM2A His-tag Protein, CF

• MGC33530
• V-set and transmembrane domain containing 2
• V-set and transmembrane domain containing 2A
• V-set and transmembrane domain-containing protein 2A
• VSTM2
• VSTM2A

Background

V-set and transmembrane domain-containing protein 2A (VSTM2A) is a secreted glycoprotein that is expressed by committed preadipocytes. N-linked glycosylation is crucial for its secretion, but not for preadipocyte cell differentiation activity. It is expressed during adipocyte development and its over-expression promotes adipogenesis (1). VSTM2A is highly expressed in the brain and Vstm2a was identified as an enigmatic gene that is highly produced in mouse brain (1, 2). A positive association has been observed between Vstm2a and Pparg2. VSTM2A plays a role in the regulation of the early stage of white and brown preadipocyte cell differentiation. It promotes adipogenic commitment of preadipocytes by increasing gene expression of the transcription factor PPARG in a BMP4-dependent signaling pathway (1, 3). In humans, two isoforms (1 and 2) exist due to alternative splicing. Human VSTM2A is synthesized either as a 236 amino acid (aa) (Isoform 1) or a 244 aa (Isoform 2) precursor that contains a 24 aa signal sequence followed by the VSTM2A domain. Human Isoform 2 VSTM2A shares 78% aa sequence identity with mouse and rat VSTM2A. Our in house data show that VSTM2A inhibits the human T cell activation, including anti-CD3 induced IL-2 and IFN-gamma secretion, and T cell proliferation.

1. Secco, B. et al. (2017) Cell Rep. 18:93.
2. Pandey, A.K. et al. (2014) PloS One. 9:e88889.
3. Berry, D.C. et al. (2013) Development. 140:3939.

Bioinformatics

• Uniprot:
  • Q8TAG5-2()